Standardized Pathology Report for Colorectal Cancer, 2nd Edition

키워드

참고문헌 (102)

1. 장희진, "대장암 병리보고서 기재사항 표준화", Journal of Pathology and Translational Medicine, 40(3), pp.193~203 (2006), 대한병리학회
2. Annual report of cancer statistics in Korea in 2015, "Ministry of Health and Welfare", Ministry of Health and Welfare, ~ (2017)
3. Kakar S, "Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum, version 4.0.0.0", College of American Pathologists, ~ (2017)
4. Amin MB, "AJCC cancer staging system" (2017), Springer
5. WHO Classification of Tumours Editorial Board, "WHO classification of tumours: digestive system tumours" (2019), World Health Organization
6. Fritz AG, "International classification of diseases for oncology (ICD-O). 3rd ed. 1st rev", International Agency for Research on Cancer, ~ (2013)
7. Langman G, "Association of Coloproctology of Great Britain & Ireland (ACPGBI): guidelines for the management of cancer of the colon, rectum and anus (2017)-pathology standards and datasets", Colorectal Dis, 19(Suppl 1), pp.74~81 (2017)
8. Nagtegaal I, "Morphological changes in tumour type after radiotherapy are accompanied by changes in gene expression profile but not in clinical behaviour", J Pathol, 204, pp.183~192 (2004)
9. Verdu M, "Clinicopathological and molecular characterization of colorectal micropapillary carcinoma", Mod Pathol, 24, pp.729~738 (2011)
10. Lee HJ, "Colorectal micropapillary carcinomas are associated with poor prognosis and enriched in markers of stem cells", Mod Pathol, 26, pp.1123~1131 (2013)
11. Nassar H, "Carcinomas with micropapillary morphology : clinical significance and current concepts", Adv Anat Pathol, 11, pp.297~303 (2004)
12. Xu F, "Micropapillary component in colorectal carcinoma is associated with lymph node metastasis in T1 and T2Stages and decreased survival time in TNM stages I and II", Am J Surg Pathol, 33, pp.1287~1292 (2009)
13. Haupt B, "Colorectal adenocarcinoma with micropapillary pattern and its association with lymph node metastasis", Mod Pathol, 20, pp.729~733 (2007)
14. Jakubowska K, "Invasive micropapillary component and its clinico-histopathological significance in patients with colorectal cancer", Oncol Lett, 12, pp.1154~1158 (2016)
15. Tuppurainen K, "Morphology and microsatellite instability in sporadic serrated and non-serrated colorectal cancer", J Pathol, 207, pp.285~294 (2005)
16. Patai AV, "Serrated pathway : alternative route to colorectal cancer", World J Gastroenterol, 19, pp.607~615 (2013)
17. Mäkinen MJ, "Colorectal serrated adenocarcinoma", Histopathology, 50, pp.131~150 (2007)
18. Barresi V, "Prognostic significance of grading based on the counting of poorly differentiated clusters in colorectal mucinous adenocarcinoma", Hum Pathol, 46, pp.1722~1729 (2015)
19. Bosman FT, "WHO classification of tumours of the digestive system" (2010), International Agency for Research on Cancer
20. Kojima M, "Intramucosal colorectal carcinoma with invasion of the lamina propria : a study by the Japanese Society for Cancer of the Colon and Rectum", Hum Pathol, 66, pp.230~237 (2017)
21. Panarelli NC, "Histologic features and cytologic techniques that aid pathologic stage assessment of colonic adenocarcinoma", Am J Surg Pathol, 37, pp.1252~1258 (2013)
22. Uehara K, "Clinicopathological significance of microscopic abscess formation at the invasive margin of advanced low rectal cancer", Br J Surg, 94, pp.239~243 (2007)
23. Smith KD, "Clinical significance of acellular mucin in rectal adenocarcinoma patients with a pathologic complete response to preoperative chemoradiation", Ann Surg, 251, pp.261~264 (2010)
24. Kang CM, "Prevalence and clinical significance of cellular and acellular mucin in patients with locally advanced mucinous rectal cancer who underwent preoperative chemoradiotherapy followed by radical surgery", Colorectal Dis, 18, pp.O10~6 (2016)
25. Kitajima K, "Correlations between lymph node metastasis and depth of submucosal invasion in submucosal invasive colorectal carcinoma : a Japanese collaborative study", J Gastroenterol, 39, pp.534~543 (2004)
26. Bosch SL, "Predicting lymph node metastasis in pT1 colorectal cancer : a systematic review of risk factors providing rationale for therapy decisions", Endoscopy, 45, pp.827~834 (2013)
27. Haggitt RC, "Prognostic factors in colorectal carcinomas arising in adenomas : implications for lesions removed by endoscopic polypectomy", Gastroenterology, 89, pp.328~336 (1985)
28. Kikuchi R, "Management of early invasive colorectal cancer : risk of recurrence and clinical guidelines", Dis Colon Rectum, 38, pp.1286~1295 (1995)
29. Watanabe T, "Japanese Society for Cancer of the Colon and Rectum(JSCCR)guidelines 2016 for the treatment of colorectal cancer", Int J Clin Oncol, 23, pp.1~34 (2018)
30. Betge J, "Intramural and extramural vascular invasion in colorectal cancer : prognostic significance and quality of pathology reporting", Cancer, 118, pp.628~638 (2012)
31. 김우호, "위암 병리보고서 기재사항 표준화", Journal of Pathology and Translational Medicine, 39(2), pp.106~113 (2005), 대한병리학회
32. Liebig C, "Perineural invasion is an independent predictor of outcome in colorectal cancer", J Clin Oncol, 27, pp.5131~5137 (2009)
33. Liebig C, "Perineural invasion in cancer : a review of the literature", Cancer, 115, pp.3379~3391 (2009)
34. Gibson JA, "Pathology of premalignant colorectal neoplasia", Dig Endosc, 28, pp.312~323 (2016)
35. Rex DK, "Serrated lesions of the colorectum : review and recommendations from an expert panel", Am J Gastroenterol, 107, pp.1315~1329 (2012)
36. Bateman AC, "UK guidance for the pathological reporting of serrated lesions of the colorectum", J Clin Pathol, 68, pp.585~591 (2015)
37. Liu C, "Sessile serrated adenomas with dysplasia : morphological patterns and correlations with MLH1 immunohistochemistry", Mod Pathol, 30, pp.1728~1738 (2017)
38. Chetty R, "Traditional serrated adenomas(TSAs)admixed with other serrated(socalled precursor)polyps and conventional adenomas : a frequent occurrence", J Clin Pathol, 68, pp.270~273 (2015)
39. Anwar MA, "Outcome of acutely perforated colorectal cancers : experience of a single district general hospital", Surg Oncol, 15, pp.91~96 (2006)
40. Mitrovic B, "Tumor budding in colorectal carcinoma : time to take notice", Mod Pathol, 25, pp.1315~1325 (2012)
41. Choi DH, "Indications for subsequent surgery after endoscopic resection of submucosally invasive colorectal carcinomas : a prospective cohort study", Dis Colon Rectum, 52, pp.438~445 (2009)
42. Ueno H, "Risk factors for an adverse outcome in early invasive colorectal carcinoma", Gastroenterology, 127, pp.385~394 (2004)
43. Wang LM, "Tumor budding is a strong and reproducible prognostic marker in T3N0 colorectal cancer", Am J Surg Pathol, 33, pp.134~141 (2009)
44. Giger OT, "Intra-tumoral budding in preoperative biopsy specimens predicts lymph node and distant metastasis in patients with colorectal cancer", Mod Pathol, 25, pp.1048~1053 (2012)
45. Rogers AC, "Prognostic significance of tumor budding in rectal cancer biopsies before neoadjuvant therapy", Mod Pathol, 27, pp.156~162 (2014)
46. Lugli A, "Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference(ITBCC)2016", Mod Pathol, 30, pp.1299~1311 (2017)
47. Koelzer VH, "Tumor budding in colorectal cancer revisited : results of a multicenter interobserver study", Virchows Arch, 466, pp.485~493 (2015)
48. Koelzer VH, "Cytokeratinbased assessment of tumour budding in colorectal cancer : analysis in stage II patients and prospective diagnostic experience", J Pathol Clin Res, 3, pp.171~178 (2017)
49. Jass JR, "A new prognostic classification of rectal cancer", Lancet, 1, pp.1303~1306 (1987)
50. Bosch SL, "The importance of the pathologist’s role in assessment of the quality of the mesorectum", Curr Colorectal Cancer Rep, 8, pp.90~98 (2012)
51. Aklilu M, "The current landscape of locally advanced rectal cancer", Nat Rev Clin Oncol, 8, pp.649~659 (2011)
52. Bibeau F, "Locally advanced rectal cancer management: which role for the pathologist in 2011?", Ann Pathol, 31, pp.433~441 (2011)
53. Dhadda AS, "Prognostic importance of Mandard tumour regression grade following pre-operative chemo", radiotherapy for locally advanced rectal cancer, 2011, pp.47, 1138~1145
54. Mihaylova I, "Degree of tumor regression after preoperative chemo-radiotherapy in locally advanced rectal cancer-Preliminary results", Rep Pract Oncol Radiother, 16, pp.237~242 (2011)
55. Vallböhmer D, "Evaluation of histological regression grading systems in the neoadjuvant therapy of rectal cancer: do they have prognostic impact?", Int J Colorectal Dis, 27, pp.1295~1301 (2012)
56. 김수희, "What Is the Ideal Tumor Regression Grading System in Rectal Cancer Patients after Preoperative Chemoradiotherapy?", Cancer Research and Treatment, 48(3), pp.998~1009 (2016), 대한암학회
57. Mandard AM, "Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma : clinicopathologic correlations", Cancer, 73, pp.2680~2686 (1994)
58. Dworak O, "Pathological features of rectal cancer after preoperative radiochemotherapy", Int J Colorectal Dis, 12, pp.19~23 (1997)
59. Ryan R, "Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer", Histopathology, 47, pp.141~146 (2005)
60. Krasinskas AM, "EGFR Signaling in Colorectal Carcinoma", Patholog Res Int, 2011, pp.932932~ (2011)
61. Goldstein NS, "Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma : implications for a standardized scoring system", Cancer, 92, pp.1331~1346 (2001)
62. McKay JA, "Evaluation of the epidermal growth factor receptor(EGFR)in colorectal tumours and lymph node metastases", Eur J Cancer, 38, pp.2258~2264 (2002)
63. Spano JP, "Epidermal growth factor receptor signaling in colorectal cancer : preclinical data and therapeutic perspectives", Ann Oncol, 16, pp.189~194 (2005)
64. Resnick MB, "Epidermal growth factor receptor, c-MET, beta-catenin, and p53 expression as prognostic indicators in stage II colon cancer : a tissue microarray study", Clin Cancer Res, 10, pp.3069~3075 (2004)
65. de Castro-Carpeno J, "EGFR and colon cancer : a clinical view", Clin Transl Oncol, 10, pp.6~13 (2008)
66. Saltz LB, "Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor", J Clin Oncol, 22, pp.1201~1208 (2004)
67. Vallböhmer D, "Molecular determinants of cetuximab efficacy", J Clin Oncol, 23, pp.3536~3544 (2005)
68. Ogino S, "Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer", Clin Cancer Res, 11, pp.6650~6656 (2005)
69. Geiersbach KB, "Microsatellite instability and colorectal cancer", Arch Pathol Lab Med, 135, pp.1269~1277 (2011)
70. Pino MS, "Microsatellite instability in the management of colorectal cancer", Expert Rev Gastroenterol Hepatol, 5, pp.385~399 (2011)
71. Samowitz WS, "Evaluation of colorectal cancers for Lynch syndrome : practical molecular diagnostics for surgical pathologists", Mod Pathol, 28(Suppl 1), pp.S109~S113 (2015)
72. Boland CR, "Microsatellite instability in colorectal cancer", Gastroenterology, 138, pp.2073~2087 (2010)
73. Guastadisegni C, "Microsatellite instability as a marker of prognosis and response to therapy : a meta-analysis of colorectal cancer survival data", Eur J Cancer, 46, pp.2788~2798 (2010)
74. Pritchard CC, "Colorectal cancer molecular biology moves into clinical practice", Gut, 60, pp.116~129 (2011)
75. Le DT, "PD-1 blockade in tumors with mismatch-repair deficiency", N Engl J Med, 372, pp.2509~2520 (2015)
76. Le DT, "Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade", Science, 357, pp.409~413 (2017)
77. Roxburgh CS, "The role of the in situ local inflammatory response in predicting recurrence and survival in patients with primary operable colorectal cancer", Cancer Treat Rev, 38, pp.451~466 (2012)
78. Kirilovsky A, "Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients", Int Immunol, 28, pp.373~382 (2016)
79. Mlecnik B, "Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability", Immunity, 44, pp.698~711 (2016)
80. Galon J, "Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours", J Pathol, 232, pp.199~209 (2014)
81. Galon J, "Cancer classification using the Immunoscore : a worldwide task force", J Transl Med, 10, pp.205~ (2012)
82. Sepulveda AR, "Molecular biomarkers for the evaluation of colorectal cancer : guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology", J Clin Oncol, 35, pp.1453~1486 (2017)
83. Zaanan A, "Role of deficient DNA mismatch repair status in patients with stage III colon cancer treated with FOLFOX adjuvant chemotherapy : a pooled analysis from 2 randomized clinical trials", JAMA Oncol, 4, pp.379~383 (2018)
84. Sargent DJ, "Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer", J Clin Oncol, 28, pp.3219~3226 (2010)
85. Overman MJ, "Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer(CheckMate 142) : an open-label, multicentre, phase 2 study", Lancet Oncol, 18, pp.1182~1191 (2017)
86. Umar A, "Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer(Lynch syndrome)and microsatellite instability", J Natl Cancer Inst, 96, pp.261~268 (2004)
87. Boland CR, "A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition : development of international criteria for the determination of microsatellite instability in colorectal cancer", Cancer Res, 58, pp.5248~5257 (1998)
88. Adar T, "A tailored approach to BRAF and MLH1 methylation testing in a universal screening program for Lynch syndrome", Mod Pathol, 30, pp.440~447 (2017)
89. Buhard O, "Multipopulation analysis of polymorphisms in five mononucleotide repeats used to determine the microsatellite instability status of human tumors", J Clin Oncol, 24, pp.241~251 (2006)
90. Goel A, "An optimized pentaplex PCR for detecting DNA mismatch repair-deficient colorectal cancers", PLoS One, 5, pp.e9393~ (2010)
91. Van Cutsem E, "ESMO consensus guidelines for the management of patients with metastatic colorectal cancer", Ann Oncol, 27, pp.1386~1422 (2016)
92. Amado RG, "Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer", J Clin Oncol, 26, pp.1626~1634 (2008)
93. Douillard JY, "Panitumumab-FOLFOX4treatment and RAS mutations in colorectal cancer", N Engl J Med, 369, pp.1023~1034 (2013)
94. Rui Y, "K-Ras mutation and prognosis of colorectal cancer : a meta-analysis", Hepatogastroenterology, 62, pp.19~24 (2015)
95. Phipps AI, "Association between molecular subtypes of colorectal cancer and patient survival", Gastroenterology, 148, pp.77~87 (2015)
96. Sinicrope FA, "Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes", Gastroenterology, 148, pp.88~99 (2015)
97. Taieb J, "Prognostic value of BRAF and KRAS mutations in MSI and MSS stage III colon cancer", J Natl Cancer Inst, 109, pp.djw272~ (2017)
98. Schirripa M, "BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection", Br J Cancer, 112, pp.1921~1928 (2015)
99. Wang L, "BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair", Cancer Res, 63, pp.5209~5212 (2003)
100. Loes IM, "Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases", Int J Cancer, 139, pp.647~656 (2016)
101. Di Nicolantonio F, "Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer", J Clin Oncol, 26, pp.5705~5712 (2008)
102. Pietrantonio F, "Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab : a meta-analysis", Eur J Cancer, 51, pp.587~594 (2015)

관련 논문AI추천